Please note that the contents in this website are current as of the date of the press announcement and may be subject to change without prior notice. Information in each release, including the product availability, specification, prices, contacts, are those at the time of publication.
For Investors Relations news and news releases from Fujifilm and FUJIFILM Business Innovation for 2019 and before, please click：
- Mar 23, 2022
- Fujifilm to issue a 120 billion yen social bond offering in Japan
- Mar 23, 2022
- Fujifilm to Acquire Shenandoah Biotechnology, Leading Manufacturer of Recombinant Proteins (Fujifilm)
- Mar 22, 2022
-
Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business
Amendment in relation to a return of domestic marketing rights for a product (Fujifilm) - Mar 11, 2022
- Fujifilm to terminate the enrollment of subjects in the phase III clinical trial of anti-influenza drug Avigan® Tablet in Japan, targeting COVID-19 patients (Fujifilm)
- Mar 9, 2022
- FUJIFILM Holdings selected as a Health & Productivity Stock
- Mar 4, 2022
- FUJIFILM Holdings to donate $2M to support humanitarian efforts in Ukraine
- Feb 9, 2022
- Fujifilm launches life sciences strategic investment fund focused on emerging companies with high impact biotechnology (Fujifilm)
- Jan 27, 2022
- Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. (Fujifilm)